WO2004024089A3 - Inhibition or activation of adam9 and adam15 for treatment of vascularization-related disease and wound healing - Google Patents
Inhibition or activation of adam9 and adam15 for treatment of vascularization-related disease and wound healing Download PDFInfo
- Publication number
- WO2004024089A3 WO2004024089A3 PCT/US2003/028751 US0328751W WO2004024089A3 WO 2004024089 A3 WO2004024089 A3 WO 2004024089A3 US 0328751 W US0328751 W US 0328751W WO 2004024089 A3 WO2004024089 A3 WO 2004024089A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- adam
- adam9
- adam15
- neovascularization
- inhibition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Inhibition of neovascularization is achieved by exposing a tissue susceptible to neovascularization to a therapeutic agent effective to inhibit ADAM 9 and/or ADAM 15. The therapeutic agent may be, for example, an antibody, a small molecule therapeutic, an antisense or RNAi therapeutic, or an agent for introducing targeted mutations in the genetic sequence for ADAM9 and/or ADAM 15. Thus, an individual suffering from a condition associated with pathological neovascularization is treated by administration of a therapeutic agent effective to inhibit a ADAM 9 or ADAM 15. Activation of ADAM9 or ADAM 15 can be used for promotion of neovascularization, for example to facilitate wound healing, perfusion or circulation. In this case, the therapeutic agent used is one which enhances the active amount of ADAM9 and/or ADAM15. Inhibition or activation of ADAM9 and/or ADAM15 in accordance with the methods of the invention provides an attractive alternative to targeting of other ADAM species, such as ADAM10, because neither ADAM9 nor ADAM15 appears to be essential for development or maintenance. Thus, side effects are minimised.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2003270625A AU2003270625A1 (en) | 2002-09-11 | 2003-09-11 | Inhibition or activation of adam9 and adam15 for treatment of vascularization-related disease and wound healing |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40985802P | 2002-09-11 | 2002-09-11 | |
| US60/409858 | 2002-09-11 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2004024089A2 WO2004024089A2 (en) | 2004-03-25 |
| WO2004024089A3 true WO2004024089A3 (en) | 2005-02-03 |
Family
ID=31994015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2003/028751 WO2004024089A2 (en) | 2002-09-11 | 2003-09-11 | Inhibition or activation of adam9 and adam15 for treatment of vascularization-related disease and wound healing |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2003270625A1 (en) |
| WO (1) | WO2004024089A2 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7309487B2 (en) * | 2004-02-09 | 2007-12-18 | George Inana | Methods and compositions for detecting and treating retinal diseases |
| MX2007009222A (en) * | 2005-02-02 | 2008-01-16 | Raven Biotechnologies Inc | Adam-9 modulators. |
| EP2243488B1 (en) * | 2006-01-19 | 2013-08-14 | Eyegene Inc. | Pharmaceutical composition for treating vascular-related diseases comprising peptide |
| GB2453589A (en) * | 2007-10-12 | 2009-04-15 | King S College London | Protease inhibition |
| CN101946003B (en) * | 2008-02-14 | 2013-05-15 | 株式会社遗传科技 | Anti-adam-15 antibodies and utilization of the same |
| WO2009118660A2 (en) * | 2008-03-24 | 2009-10-01 | Salman Rahman | Adam-15 antibodies and immunogenic peptides |
| JP2012517821A (en) * | 2009-02-19 | 2012-08-09 | ガラパゴス・ナムローゼ・フェンノートシャップ | Identification method and compound useful for diagnosis and treatment of diseases including inflammation |
| US9732157B2 (en) | 2010-10-01 | 2017-08-15 | Salman Rahman | Methods for the development of metzincin-selective catalytic cleft directed antibodies for therapeutic and diagnostic applications |
| EP3700521B1 (en) | 2017-10-29 | 2024-06-12 | China Medical University | Use of adam9 inhibitor compound and composition including adam9 inhibitor compound |
| TWI735210B (en) * | 2019-04-26 | 2021-08-01 | 中國醫藥大學 | Use of adam9 inhibitor as immune modulator |
| CN114578052A (en) * | 2022-03-08 | 2022-06-03 | 新疆医科大学第一附属医院 | Application of ADAM10 in occlusive cardiovascular and cerebrovascular diseases |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6465468B1 (en) * | 1999-03-22 | 2002-10-15 | Darwin Discovery Limited | Hydroxamic and carboxylic acid derivatives |
-
2003
- 2003-09-11 AU AU2003270625A patent/AU2003270625A1/en not_active Abandoned
- 2003-09-11 WO PCT/US2003/028751 patent/WO2004024089A2/en not_active Application Discontinuation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6465468B1 (en) * | 1999-03-22 | 2002-10-15 | Darwin Discovery Limited | Hydroxamic and carboxylic acid derivatives |
Non-Patent Citations (1)
| Title |
|---|
| ROGHANI ET AL: "Metalloprotease-Disintergrin MDC 9: Intracellular maturation and catalytic activity", J. OF BIO. CHEM., vol. 274, no. 6, 1999, pages 3531 - 3540, XP000919470 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003270625A1 (en) | 2004-04-30 |
| WO2004024089A2 (en) | 2004-03-25 |
| AU2003270625A8 (en) | 2004-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX336710B (en) | Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases. | |
| ATE355374T1 (en) | THERAPEUTIC AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF AMYLOIDOGENIC DISEASES | |
| ATE412646T1 (en) | THERAPEUTIC AGENTS SUITABLE FOR THE TREATMENT OF PAIN | |
| MXPA05006940A (en) | Therapeutic formulations for the treatment of beta-amyloid related diseases. | |
| WO2004068931A3 (en) | Amphiregulin antibodies and their use to treat cancer and psoriasis | |
| WO2004069190A3 (en) | Combination therapy for treating protein deficiency disorders | |
| EA200601799A1 (en) | HYDRAZIDE-CONTAINING COMPOUNDS - CFTR INHIBITORS AND THEIR APPLICATION | |
| JP2014516029A5 (en) | Therapeutic agent containing RG cysteic acid peptide | |
| HK1096857A1 (en) | Medicamentously targeted local lipolysis | |
| WO2004024089A3 (en) | Inhibition or activation of adam9 and adam15 for treatment of vascularization-related disease and wound healing | |
| EA200971053A1 (en) | METHODS OF TREATMENT OF THE LEAD ULCERS | |
| WO2008157787A3 (en) | Hydroxylated tolans and related compounds in the treatment of cancer | |
| ATE422357T1 (en) | USE OF ALLOPURINOL TO TREAT HYPERTENSION | |
| WO2008021149A3 (en) | Compositions, devices and methods for treatment of huntington's disease through intracranial delivery of sirna | |
| EP1758998A4 (en) | Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases | |
| DE69725879D1 (en) | USE OF p-AMINOPHENOL DERIVATIVES FOR THE PRODUCTION OF PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | |
| MY134562A (en) | Methods and compositions to treat conditions associated with neovascularization | |
| ATE287722T1 (en) | AGENT FOR TREATING MALIGNANT DISEASES USING THE PROTEIN YB-1 | |
| DE60111620D1 (en) | ACTIVATED PROTEIN C FOR THE TREATMENT OF PANCREATITIS | |
| ATE496992T1 (en) | TREATMENT OF IGAI DEPOSITION DISEASE | |
| ATE285773T1 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NEUROLOGICAL DISEASES | |
| ATE302011T1 (en) | PONAZURIL FOR THE TREATMENT OF DISEASES CAUSED BY COCCIDIA NEUROLOGICAL AND ABORTIGENICS | |
| DE60036697D1 (en) | UTEROGLOBIN FOR THE TREATMENT OF IGA-MEDIATED AUTOIMMUNE DISEASES | |
| ITMI20030860A1 (en) | METHOD FOR SELECTIVE INHIBITION OF THE N-MYC GENE | |
| RU2007112409A (en) | SIMULTANEOUS RECEPTION OF TIGICYCLINE AND DIGOXIN |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: JP |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |